Ultragenyx to Sell FDA Priority Review Voucher for $210 Million
Ultragenyx Pharmaceutical (RARE) announced a deal to sell an FDA priority review voucher it received in connection with the approval of its rare disease therapy, Genglycos. The company will receive $210 million from this transaction. The priority review voucher was obtained when the U.S. Food and Drug Administration approved pariglasgene brecaparvovec-opnr (Genglycos) in August 2024 as a treatment for rare diseases, expediting regulatory reviews of future therapies. Priority review vouchers are valuable tools that allow companies to fast-track new drug applications. The announcement led to an increase in Ultragenyx’s stock price on Wednesday, reflecting investor optimism about the financial benefit and potential strategic value from this transaction.
Tickers: $RARE
Topics: FDA Approval Gene Therapy Pharmaceuticals Priority Review Voucher